

IN THE CLAIMS:

Please cancel claims 1-21 and add new divisional claims 22-30.

Claims 1-21 (canceled).

22. (new): Use of a cyclosporine in association with hyaluronic acid or one of its salts and with polysorbate 80 for the preparation of a formulation in the form of an aqueous solution intended for topical ophthalmic use.

23. (new): Use according to claim 22 wherein the formulation comprises 0.02 to 2 % by weight of cyclosporine, 0.01 to 2 % by weight of hyaluronic acid or one of its salts, and 0.5 to 40 % by weight of polysorbate 80, based on the formulation's total weight.

24. (new): Use according to claim 22, wherein the cyclosporine is a cyclosporine A.

25. (new): Use according to claim 22, wherein the hyaluronic acid or its salt has a weight-average molecular weight not inferior to 1,300,000 daltons.

26. (new): Use according to claim 25, wherein the hyaluronic acid or its salt has a weight-average molecular weight situated in the region from 1,300,000 to 3,000,000 daltons.


27. (new): Use according to claim 22, wherein the hyaluronic acid is present as alkali metal or alkaline-earth metal hyaluronate.

28. (new): Use according to claim 27, wherein the hyaluronic acid is present as sodium hyaluronate.

29. (new): Use of a formulation comprising a cyclosporine, hyaluronic acid or one of its salts, and polysorbate 80, for the treatment of conditions selected from the group consisting of keratoconjunctivitis sicca (KCS), Sjögren's syndrome, dry-eye syndrom and chronic vernal keratoconjunctivitis.

30. (new): Use according to claim 22, wherein the formulation is intended for use as a post-operative prophylactic in keratoplasty.

Respectfully submitted

By: 
Clifford W. Browning
Reg. No. 32,201
Woodard, Emhardt et al. LLP
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456

#252242